CIMZIA History

A History of Helping Adults Across Six
Chronic Inflammatory Diseases

More than 200,000 people treated with CIMZIA since 2008

First approved by the FDA in 2008 for adults with moderate to severe Crohn’s disease (not helped enough by usual treatments), CIMZIA was later approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate to severe plaque psoriasis (in adults who may benefit from taking injections or pills [systemic therapy] or phototherapy [treatment using ultraviolet light alone or with pills]), and non-radiographic axial spondyloarthritis with measures of inflammation.

Today, thousands of doctors choose CIMZIA for their adult patients with chronic inflammatory conditions.

CIMZIA Has Been Studied in Over 80 Clinical
Trials Across All Approved Indications*

CIMZIA was most recently FDA-approved in 2019 to treat adults with active nr-axSpA.

*Includes studies related to FDA-approved indications of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and non-radiographic axial spondyloarthritis, as well as additional ongoing and completed research.

Have you been prescribed CIMZIA? Join our mailing list for ongoing support.